SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 24, 2004
ENCYSIVE PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
<Table>
DELAWARE 0-20117 13-3532643
(State of Incorporation) (Commission File Number) (IRS Employer Identification No.)
- -------------------------------------------------------------------------------------------
</Table>
6700 WEST LOOP, 4TH FLOOR
BELLAIRE, TEXAS 77401
(Address of Registrant's principal executive offices)
(713) 796-8822
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 Press Release.
ITEM 9. REGULATION FD DISCLOSURE
On May 24, 2004, Encysive Pharmaceuticals Inc. issued a press release
announcing that investigators presented data from clinical studies of Thelin(TM)
(sitaxsentan) in pulmonary arterial hypertension (PAH), at the American Thoracic
Society's (ATS) 100th International Conference in Orlando, Florida. The full
text of the press release is furnished herewith as Exhibit 99.1.
[SIGNATURE PAGE FOLLOWS]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENCYSIVE PHARMACEUTICALS INC.
Date: May 24, 2004 By: /s/ Stephen L. Mueller
-------------------------------------------
Stephen L. Mueller
Vice-President, Finance and Administration
Secretary and Treasurer
EXHIBIT INDEX
<Table>
<Caption>
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
99.1 Press Release.
</Table>